These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

377 related items for PubMed ID: 17699437

  • 21. Calcineurin inhibitor toxicity in renal allografts: morphologic clues from protocol biopsies.
    Sharma A, Jain S, Gupta R, Guleria S, Agarwal S, Dinda A.
    Indian J Pathol Microbiol; 2010; 53(4):651-7. PubMed ID: 21045386
    [Abstract] [Full Text] [Related]

  • 22. An up-date review on individualized dosage adjustment of calcineurin inhibitors in organ transplant patients.
    Masuda S, Inui K.
    Pharmacol Ther; 2006 Oct; 112(1):184-98. PubMed ID: 16759707
    [Abstract] [Full Text] [Related]

  • 23. The CARI guidelines. Calcineurin inhibitors in renal transplantation: therapeutic drug monitoring.
    Trevillian P, Caring for Australians with Renal Impairment (CARI).
    Nephrology (Carlton); 2007 Feb; 12 Suppl 1():S57-65. PubMed ID: 17316283
    [No Abstract] [Full Text] [Related]

  • 24. Quantitative analysis of regulatory T cells in kidney graft recipients: a relationship with calcineurin inhibitor level.
    Calvo-Turrubiartes M, Romano-Moreno S, García-Hernández M, Chevaile-Ramos JA, Layseca-Espinosa E, González-Amaro R, Portales-Pérez D.
    Transpl Immunol; 2009 May; 21(1):43-9. PubMed ID: 19233271
    [Abstract] [Full Text] [Related]

  • 25. Increase in renal vascular resistance after intake of cyclosporin A and tacrolimus and reversal by nitroglycerin spray: a study in patients with stable renal allograft function.
    Weingart C, Leingärtner T, Bergler T, Krüger B, Böger C, Mack M, Banas B, Krämer BK.
    Int J Clin Pharmacol Ther; 2006 Sep; 44(9):422-7. PubMed ID: 16995330
    [Abstract] [Full Text] [Related]

  • 26. Impaired erythropoietin production in liver transplant recipients: the role of calcineurin inhibitors.
    Bardet V, Junior AP, Coste J, Lecoq-Lafon C, Chouzenoux S, Bernard D, Soubrane O, Lacombe C, Calmus Y, Conti F.
    Liver Transpl; 2006 Nov; 12(11):1649-54. PubMed ID: 17058250
    [Abstract] [Full Text] [Related]

  • 27. Evidence of different pharmacokinetics between cyclosporine and tacrolimus in renal transplant recipients: why cyclosporine is monitored by C2 level and tacrolimus by trough level.
    Takeuchi H, Matsuno N, Hirano T, Toraishi T, Konno O, Nakamura Y, Iwamoto H, Hama K, Unezaki S, Nagao T.
    Transplant Proc; 2008 Sep; 40(7):2240-2. PubMed ID: 18790203
    [Abstract] [Full Text] [Related]

  • 28. The combined effect of pre-transplant triglyceride levels and the type of calcineurin inhibitor in predicting the risk of new onset diabetes after renal transplantation.
    Porrini E, Delgado P, Alvarez A, Cobo M, Pérez L, González-Posada JM, Hortal L, Gallego R, García JJ, Checa M, Morales A, Salido E, Hernández D, Torres A.
    Nephrol Dial Transplant; 2008 Apr; 23(4):1436-41. PubMed ID: 18029372
    [Abstract] [Full Text] [Related]

  • 29. Suitable calcineurin inhibitor concentrations for liver transplant recipients in the Chinese population.
    Chen YB, Li SD, Ju BL, Shi XJ, Lu F, Hu DK, Yu CH, Dong JH.
    Transplant Proc; 2011 Jun; 43(5):1751-3. PubMed ID: 21693271
    [Abstract] [Full Text] [Related]

  • 30. [Therapeutic monitoring of immunosuppressive drugs: interest of calcineurin activity assessment in liver transplantation].
    Blanchet B.
    Ann Pharm Fr; 2008 Mar; 66(2):96-101. PubMed ID: 18570908
    [Abstract] [Full Text] [Related]

  • 31. Significant impact of gene polymorphisms on tacrolimus but not cyclosporine dosing in Asian renal transplant recipients.
    Loh PT, Lou HX, Zhao Y, Chin YM, Vathsala A.
    Transplant Proc; 2008 Jun; 40(5):1690-5. PubMed ID: 18589174
    [Abstract] [Full Text] [Related]

  • 32. Immunological monitoring of calcineurin inhibitors for predicting cytomegalovirus infection in kidney transplant recipients.
    Couzi L, Thiébaut R, Carron JC, Moreau JF, Merville P, Taupin JL.
    Transplantation; 2008 Oct 27; 86(8):1060-7. PubMed ID: 18946343
    [Abstract] [Full Text] [Related]

  • 33. Minimization of calcineurin inhibitors to improve long-term outcomes in kidney transplantation.
    Golshayan D, Pascual M.
    Transpl Immunol; 2008 Nov 27; 20(1-2):21-8. PubMed ID: 18775494
    [Abstract] [Full Text] [Related]

  • 34. Individualizing calcineurin inhibitor therapy in renal transplantation--current limitations and perspectives.
    Press RR, de Fijter JW, Guchelaar HJ.
    Curr Pharm Des; 2010 Nov 27; 16(2):176-86. PubMed ID: 20205663
    [Abstract] [Full Text] [Related]

  • 35. Late conversion from calcineurin inhibitor-based to sirolimus-based immunosuppression due to chronic toxicity: a prospective study with protocol biopsy amendment.
    Uslu A, Töz H, Sen S, Alkan FT, Nart A, Aykas A, Doğan M, Postaci H, Sahin T, Simşek C.
    Transplant Proc; 2009 Mar 27; 41(2):756-63. PubMed ID: 19328973
    [Abstract] [Full Text] [Related]

  • 36. [Immunosuppressive therapy without calcineurin inhibitors for renal transplants? Perhaps we should be cautions...].
    Fasoli G.
    G Ital Nefrol; 2007 Mar 27; 24(2):110. PubMed ID: 17458825
    [No Abstract] [Full Text] [Related]

  • 37. Fifteen years of clinical studies and clinical practice in renal transplantation: reviewing outcomes with de novo use of sirolimus in combination with cyclosporine.
    Kahan BD.
    Transplant Proc; 2008 Dec 27; 40(10 Suppl):S17-20. PubMed ID: 19100899
    [Abstract] [Full Text] [Related]

  • 38. Excellent long-term results in de novo renal transplant recipients treated with proliferation signal inhibitors and reduced calcineurin inhibitors exposure.
    Carmellini M, Collini A, Ruggieri G, Garosi G, Bernini M.
    Transplant Proc; 2008 Dec 27; 40(6):1858-61. PubMed ID: 18675070
    [Abstract] [Full Text] [Related]

  • 39. Optimal dose and target trough level in cyclosporine and tacrolimus conversion in renal transplantation as evaluated by lymphocyte drug sensitivity and pharmacokinetic parameters.
    Takeuchi H, Okuyama K, Konno O, Jojima Y, Akashi I, Nakamura Y, Iwamoto H, Hama K, Iwahori T, Uchiyama M, Ashizawa T, Matsuno N, Nagao T, Hirano T, Oka K.
    Transplant Proc; 2005 May 27; 37(4):1745-7. PubMed ID: 15919452
    [Abstract] [Full Text] [Related]

  • 40. A transient increase of calcineurin phosphatase activity in living-donor kidney transplant recipients with acute rejection.
    Fukudo M, Yano I, Katsura T, Ito N, Yamamoto S, Kamoto T, Ogawa O, Inui K.
    Drug Metab Pharmacokinet; 2010 May 27; 25(5):411-7. PubMed ID: 20834189
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 19.